Available online **www.ijpras.com**

International Journal of Pharmaceutical Research & Allied Sciences, 2026, 15(3):25-37
https://doi.org/10.51847/iXIKkeHlj0



Original Article

ISSN : 2277-3657
CODEN(USA) : IJPRPM

Precision Nanomedicine Requires Matching Carrier Adaptation to Disease Microenvironment Dynamics

George Wilson[1]*, Chloe Bennett[2], Ethan Wright[1], Jack Turner[3]

[1]*Department of Precision Nanomedicine and Carrier Adaptation, Faculty of Pharmacy, University of Dundee, Dundee, United Kingdom.*
[2]*Department of Disease Microenvironment Dynamics, Faculty of Pharmacy, Newcastle University, Newcastle, United Kingdom.*
[3]*Department of Adaptive Nanomedicines, Faculty of Pharmacy, University of Aberdeen, Aberdeen, United Kingdom.*

***Email:** g.wilson@dundee.ac.uk*

ABSTRACT

Precision nanomedicine is often framed as increasingly selective recognition of disease-associated molecular targets or increasingly sophisticated responsiveness to pathological stimuli. Both strategies can fail when the biological state that governs carrier access, transformation, and payload release changes across space or during treatment. Tumor vasculature, extracellular matrix, oxygenation, acidity, enzyme activity, redox balance, immune composition, and stromal organization are neither uniform nor temporally fixed. Consequently, a carrier optimized for one microenvironmental state may become poorly matched when it reaches another compartment or when therapy remodels the disease itself. This Mechanistic Perspective argues that carrier adaptation should therefore be evaluated against the sequence of biological states encountered during delivery rather than against stimulus responsiveness in isolation. Evidence from vascular transport, microenvironment-responsive materials, stromal and immune remodeling, and sequential release systems is used to distinguish access, activation, trafficking, and payload-availability problems. We propose that precision nanomedicine should treat microenvironmental matching as a time-dependent, multiscale requirement in which responsiveness is useful only when the relevant trigger is accessible, sufficiently discriminating, encountered in the intended compartment, and synchronized with payload action. The framework is conceptual and requires longitudinal, stage-aware validation before predictive or clinical use.

Keywords: *Precision nanomedicine, Tumor microenvironment, Stimulus-responsive delivery, Nanoparticle transport, Controlled drug release, Spatial heterogeneity*

Received: 09 April 2026; **Revised:** 22 July 2026; **Accepted:** 26 July 2026

INTRODUCTION

Nanocarriers can protect therapeutic cargo and alter its disposition, but successful delivery remains a sequence of separable operations: cellular entry, intracellular trafficking, escape from restrictive compartments, subcellular localization, and controlled release may each impose a distinct bottleneck [1]. Improving one step therefore does not establish that a formulation has solved the delivery problem as a whole. This distinction becomes particularly important in oncology, where engineered changes in distribution and release coexist with immunological, pharmacokinetic, toxicological, and translational constraints that can limit clinical performance [2].

Precision nanomedicine has nevertheless tended to treat biological precision as a property that can be engineered primarily into the carrier. Ligand affinity, stimulus-sensitive bonds, charge switching, degradable structures, and

© 2026 The International Journal of Pharmaceutical Research and Allied Sciences (IJPRAS). **Open Access** - This article is under the **CC BY NC SA** license (https://creativecommons.org/licenses/by-nc-sa/4.0).

biomimetic coatings are valuable design variables, but they act inside a biological environment that is itself heterogeneous. Spatial and single-cell analyses increasingly depict the tumor microenvironment as an arrangement of distinct endothelial states, stromal structures, metabolic niches, proteolytic landscapes, and immune configurations rather than as a tumor-wide average [3]. A carrier may therefore possess an appropriate molecular response yet encounter the corresponding signal at the wrong location, after inadequate tissue access, or at a time when the disease state has changed.

This Perspective develops a proposed carrier–microenvironment matching principle. The central distinction is between designing a carrier that *can respond* and establishing that its response is *matched to the state encountered during delivery*. Matching is considered across four analytically separate functions: access to the relevant tissue or cellular compartment, acquisition or preservation of an appropriate biological identity, activation or transformation under the intended condition, and release of pharmacologically available payload at a useful time. The framework does not assume that dynamic carriers are intrinsically superior to stable formulations. Rather, it identifies when adaptive behavior creates useful conditionality and when added responsiveness merely introduces another failure mode.

Disease microenvironments are dynamic

Pathological tissues impose barriers at several scales. Abnormal vascular architecture, altered extracellular matrix, cellular sequestration, phagocytic clearance, membrane transport, endosomal processing, and intracellular resistance can coexist, but their relative importance depends on disease, tissue, carrier, and therapeutic mechanism [4]. A useful representation of the microenvironment is therefore not a single descriptor such as “acidic” or “leaky.” It is a configuration of barriers and enabling states that determine what a particular carrier can physically encounter.

The same logic applies within an individual tumor. Intratumoral efficacy depends on where nanoparticles distribute, which cells they contact, how long they remain within relevant regions, and when payload becomes available relative to these events [5]. Spatially averaged tumor accumulation can consequently conceal regions with adequate vascular entry but poor interstitial penetration, or regions with favorable biochemical triggers that the carrier rarely reaches. Temporal averaging adds another distortion because perfusion, hypoxia, inflammatory state, extracellular-matrix organization, and cellular composition may change during tumor progression or treatment.

Stimulus-responsive nanomaterials demonstrate that carrier structure or function can be switched by features such as acidic conditions, reactive species, or hypoxia [6]. Yet a responsive material does not interrogate an abstract “tumor microenvironment”; it encounters a local physicochemical state after a preceding transport history. Dense extracellular matrix can independently restrict diffusion and contribute to therapeutic resistance, illustrating why biochemical responsiveness cannot compensate automatically for inadequate physical access [7]. The relevant unit of precision is thus the carrier–microenvironment encounter: a defined material state meeting a defined biological state in a defined compartment and time window.

This formulation changes the interpretation of heterogeneity. Heterogeneity is not merely noise that weakens average targeting efficiency. It can determine whether a design premise is even biologically available for execution. A carrier responsive to a tumor-associated enzyme may be appropriately engineered yet mismatched if it is retained in regions with insufficient enzyme activity. Conversely, a relatively simple carrier may remain effective where access, exposure, and payload pharmacology are robust to microenvironmental variation. Adaptation should therefore be justified by the instability of the barrier or opportunity it is intended to address.

Temporal changes in vascular access

The first matching problem is access. Conventional descriptions of tumor accumulation have often emphasized passive extravasation through structurally abnormal vessels. Direct experimental work has complicated that interpretation. In investigated tumor systems, Sindhwani and colleagues found nanoparticle entry to be dominated by active transendothelial processes rather than passage through large inter-endothelial gaps [8]. This evidence does not establish a universal route for every nanoparticle or tumor, but it demonstrates that apparent vascular permeability can arise from mechanisms other than static leakiness.

Vascular access can also be spatially concentrated. Kingston and colleagues identified nanoparticle-transport endothelial cells, showing that only a subset of tumor endothelial cells in their experimental system actively participated in nanoparticle transport and thereby influenced entry location, distribution, and cellular accessibility [9]. The implication is mechanistic rather than numerical: the vascular interface can contain localized gateways.

A bulk measure of vessel density or permeability may therefore be insufficient to specify where a carrier crosses into tissue.

Imaging approaches provide one route toward measuring this variability. Dynamic contrast-enhanced MRI coupled with pharmacokinetic modelling has been developed to characterize tumor permeability and retention non-invasively [10]. Such measurements may eventually support stratification of nanomedicine access, but they should not be interpreted automatically as predictors of therapeutic benefit. Vascular transport is an upstream event; interstitial migration, cellular uptake, intracellular trafficking, release, target engagement, and pharmacodynamics remain downstream.

Importantly, vascular access is also modifiable. Microbubble-mediated ultrasound can enhance nanoparticle delivery, yet comparative tumor models show that the magnitude and microdistribution of the response depend on properties of the microenvironment. Tumors differing in stiffness, collagen, hyaluronic acid, and blood volume did not respond identically, and increased uptake did not translate into uniformly improved penetration [11]. Such context dependence argues against treating a barrier-opening intervention as a universal correction for poor delivery.

Carrier properties also feed back into this interface. Nanoscale surface topography in polyethylene-glycol-coated bottlebrush nanoparticles altered protein-corona composition, systemic circulation, and tumor uptake in a preclinical comparison [12]. Thus, the material entering the bloodstream does not retain only its manufactured identity; biological adsorption can modify how the carrier interacts with subsequent barriers. Tumor vascular access is consequently a relationship between endothelial state and an evolving nano-bio interface.

Beyond the vessel wall, extracellular matrix and stromal architecture can restrict diffusion even when extravasation has occurred. Strategies that alter vasculature, matrix organization, or stromal components may increase accessibility in selected settings, but their effects are strongly context dependent and may introduce biological trade-offs [13]. A temporally credible matching strategy should therefore distinguish vascular entry, interstitial propagation, and later biochemical activation. Increasing one cannot be assumed to repair failure at another.

pH, hypoxia, enzymes, and redox states

Biochemical responsiveness illustrates both the promise and the principal conceptual weakness of adaptive nanomedicine. A peptide nanoparticle engineered to respond to acidic conditions, a reducing environment, and matrix metalloproteinase-2 demonstrated that several stimuli could cooperate to increase pirarubicin release [14]. This establishes the feasibility of multi-trigger logic in a defined system, but not a universal tumor-state rule. Experimental reducing agents, enzyme concentrations, incubation conditions, and formulation-specific transition properties cannot be converted directly into patient-wide thresholds.

Compartment is equally important. A dual-responsive immunotherapeutic nanomedicine used pH- and enzyme-dependent behavior to coordinate activity through the lymphatic system and tumor environment [15]. Such work illustrates that the relevant stimulus may change along the delivery route. The design question is therefore not simply whether acidity or an enzyme is associated with cancer, but whether the carrier encounters that cue in the compartment where its next transformation is required.

Acidity presents a clear example. A pH-responsive polymeric system for colorectal carcinoma was designed to undergo environment-dependent disassembly and coordinate anti-vascular and chemotherapeutic functions [16]. The mechanistic lesson is formulation-specific: protonation and structural transition can be engineered to alter payload availability. It does not justify a common acidity cutoff for solid tumors. Microregional pH, exposure duration, buffering, uptake pathway, and the carrier's own transition chemistry all determine whether an "acid-responsive" formulation actually responds appropriately.

Hypoxia creates a similar distinction between biological association and actionable trigger. A hybrid prodrug nanoassembly used hypoxia-triggered activation to combine chemotherapy with modulation of STAT3-related tumor–immune crosstalk [17]. Hypoxia-oriented biomimetic lipid nanocarriers have likewise been designed to improve delivery toward poorly oxygenated regions in lung-cancer models [18]. These approaches demonstrate that hypoxic states can be exploited, but hypoxia may simultaneously identify regions with restricted perfusion and difficult transport. A trigger can therefore become more abundant while becoming less accessible.

Hypoxia-responsive covalent organic frameworks have further coupled activatable imaging with therapeutic processes, making the state of the microenvironment observable as well as actionable [19]. This sensing–activation connection is attractive for precision delivery because it creates the possibility of verifying whether a

trigger was actually encountered. Nevertheless, therapeutic outcome cannot be attributed solely to trigger fidelity when photodynamic effects, immune activation, carrier degradation, and payload action occur together.

External stimuli make the temporal problem still more explicit. Light-triggered nanozymes can generate oxygen from endogenous hydrogen peroxide, augment photodynamic processes, promote ferroptosis-related effects, and remodel an immunosuppressive microenvironment [20]. Here the carrier is not merely responding to a pre-existing state; treatment actively changes that state. The microenvironment measured before intervention may therefore be a poor descriptor of the conditions governing subsequent release or repeat dosing.

Redox-responsive degradation similarly depends on local chemistry. A manganese-dioxide-containing nanocarrier has been used to exploit glutathione- and hydrogen-peroxide-associated conditions while releasing therapeutic components and perturbing redox homeostasis [21]. Yet "redox state" encompasses multiple oxidizing and reducing species, cellular compartments, reaction kinetics, and compensatory processes. Recent synthesis emphasizes that disease-associated redox dysregulation is spatially heterogeneous and dynamically regulated, while biosafety, pharmacokinetics, and scalable manufacture remain translational constraints for redox-responsive nanosystems [22].

Enzymatic responsiveness adds another source of mismatch. Enzyme-cleavable systems can transform disease-associated catalytic activity into carrier degradation or payload release [23]. However, expression of an enzyme does not prove that sufficient active enzyme exists where the carrier localizes, for long enough, in a biochemical environment compatible with cleavage. Enzyme abundance, catalytic activity, inhibitor presence, substrate accessibility, and carrier residence time should therefore remain separate variables.

These examples support a common inference: pH, hypoxia, enzyme activity, and redox conditions are not interchangeable "tumor triggers." They differ in spatial scale, temporal persistence, compartmentalization, measurability, and susceptibility to treatment-induced change. **Table 1** therefore treats responsiveness as a claim that must be experimentally adjudicated rather than as an intrinsic label attached to a carrier.

Table 1. Adjudicating whether a biochemical microenvironment is an actionable carrier-release condition

Evidence configuration	Interpretive alternatives	Adjudication requirement	
Carrier–barrier encounter / Payload availability question	**failure mode / Dose or time dependence / Translation boundary**	**Carrier design lever / Discriminating experiment**	**matching consequence**
Carrier–barrier encounter: Acidic extracellular tumor region Payload availability question: Does transformation occur before cellular entry without premature systemic release?	**Principal failure mode:** Trigger encountered outside the intended release compartment **Dose or time dependence:** Duration and depth of acidic exposure **Translation boundary:** Tumor acidity is spatially variable and formulation transitions are carrier-specific	**Carrier design lever:** Tunable protonation, shielding, acid-cleavable structure **Discriminating experiment:** Measure carrier state and released payload across matched extracellular pH distributions	Match the transition range to the accessible disease compartment rather than to a generic tumor pH
Carrier–barrier encounter: Hypoxic but poorly perfused region Payload availability question: Can sufficient carrier reach the low-oxygen niche before hypoxia-dependent activation is required?	**Principal failure mode:** Trigger-rich region remains transport-poor **Dose or time dependence:** Oxygen state may change during therapy **Translation boundary:** Preclinical hypoxia distributions do not define a universal human activation threshold	**Carrier design lever:** Hypoxia-activatable chemistry combined with access-promoting architecture **Discriminating experiment:** Co-map regional carrier concentration, oxygenation, and activation product	Treat access to hypoxia and response to hypoxia as separate requirements
Carrier–barrier encounter: Protease-rich stromal or invasive interface Payload availability question: Is catalytically active enzyme available where the responsive linkage resides?	**Principal failure mode:** Enzyme expression is present but effective cleavage is insufficient **Dose or time dependence:** Enzyme activity can vary with stage and treatment **Translation boundary:** Expression assays may not report local catalytic activity	**Carrier design lever:** Accessible enzyme-cleavable linker or architecture **Discriminating experiment:** Compare enzyme abundance, activity, carrier localization, and cleavage directly	Require functional enzyme–carrier colocalization before assigning responsiveness

Carrier–barrier encounter: Reducing intracellular compartment Payload availability question: Does the carrier reach the intended redox compartment before bond cleavage?	**Principal failure mode:** Premature or absent reduction because trafficking is mismatched **Dose or time dependence:** Reaction kinetics compete with trafficking and clearance **Translation boundary:** Redox chemistry differs between compartments, models, and diseases	**Carrier design lever:** Reduction-sensitive bonds or degradable inorganic components **Discriminating experiment:** Measure intracellular location and carrier-state conversion concurrently	Define redox matching at the compartment level
Carrier–barrier encounter: Oxidant-rich treatment-remodeled niche Payload availability question: Does treatment-induced oxidation enhance or disrupt the planned release sequence?	**Principal failure mode:** Trigger state changes after therapy begins **Dose or time dependence:** Strongly treatment- and cycle-dependent **Translation boundary:** Baseline biopsy may not represent post-treatment state	**Carrier design lever:** Oxidation-responsive transformation or redox-buffering function **Discriminating experiment:** Longitudinally measure reactive-species state and carrier activation	Reassess the match after microenvironment-remodeling therapy
Carrier–barrier encounter: Multi-cue region Payload availability question: Do cues occur together in the correct order rather than merely somewhere within the tumor?	**Principal failure mode:** Logical trigger set exists but lacks spatial or temporal concurrence **Dose or time dependence:** Response depends on cue sequence and persistence **Translation boundary:** Increasing design complexity increases validation burden	**Carrier design lever:** AND-like or sequential multi-responsive architecture **Discriminating experiment:** Reconstruct cue combinations and sequence under physiologically matched conditions	Use multi-trigger logic only when cue concurrence is demonstrated

A figure is required here because the central problem is not a list of stimuli but the transition of a carrier through biological states in which the same stimulus can be inaccessible, enabling, or misleading depending on location and treatment history.




Figure 1. Biochemical triggers become useful only when carrier state and microenvironment state coincide

Immune and stromal remodeling

Microenvironmental dynamics are not confined to physicochemical gradients. Immune and stromal populations can be both barriers to delivery and targets of the delivered therapy. A tumor-microenvironment-activatable nanoparticle combining immunogene delivery with macrophage-directed inhibition demonstrates that responsive formulations can alter immune composition rather than simply operate within a fixed immune background [24]. The state observed at baseline can therefore become an intermediate state produced by treatment.

Metabolism further couples tumor and immune behavior. Hypoxia, nutrient competition, toxic metabolite accumulation, and tumor-cell metabolic programs can suppress antitumor immunity, while metabolic interventions can also create off-target effects in effector immune populations [25]. For adaptive carrier design, this means that a metabolically defined "target state" cannot be judged solely by whether it is abnormal in malignant cells. The same pathway may have different functions in tumor, stromal, and immune compartments.

Stromal and immune barriers may also be mechanistically linked. In hepatocellular carcinoma models, an MMP-2-responsive nanoparticle strategy jointly targeted fibrotic and immunosuppressive components and was evaluated in systems that included a humanized immune patient-derived xenograft model [26]. Such evidence supports the feasibility of coordinated barrier modulation while remaining preclinical. It does not establish that dual remodeling will be beneficial in every fibrotic tumor, where stromal disruption can have context-dependent consequences.

Treatment can additionally modify the microenvironment through externally activated processes. Biomimetic liposomal nanovesicles used with sonodynamic therapy and immune checkpoint blockade altered the tumor immune environment in melanoma models [27]. This illustrates an important feedback: the carrier is selected for one biological state, its payload or activation changes that state, and subsequent exposure occurs under new conditions. For repeated dosing, precision therefore may require not only pretreatment stratification but reassessment of the environment created by previous treatment.

Adaptive carrier responses

Carrier adaptation should consequently be defined by *function* rather than by the mere presence of a responsive chemical bond. One form of adaptation is biological transport. In-situ cellular hitchhiking strategies exploit circulating or migrating cells to alter nanoparticle biodistribution and potentially circumvent clearance or access barriers [28]. Such systems broaden the concept of responsiveness from chemical switching to state-dependent participation in endogenous trafficking. Their translational challenges, including control, safety, carrier–cell association, and manufacturing, also show why biological sophistication should not be confused with robustness.

Within the proposed matching framework, adaptive functions can be separated into four categories. Access adaptation changes the probability of reaching a biological compartment. Identity adaptation changes how the carrier is recognized after contact with proteins, membranes, or cells. Activation adaptation transforms carrier properties after a defined cue. Release adaptation changes when and where pharmacologically available payload appears. These functions may coexist in one platform, but they should not be treated as interchangeable. A carrier may transform correctly yet fail because it never reaches the relevant niche; it may enter cells efficiently but release into a degradative compartment; or it may achieve prolonged circulation at the cost of delayed intracellular availability. The value of adaptation lies in solving a state-dependent bottleneck without creating a larger mismatch elsewhere.

Timing of payload release

The terminal step in many responsive designs is described simply as "controlled release," but temporal control is meaningful only relative to biological location and pharmacological need. Intracellular and subcellular stimulus-responsive systems are specifically designed to exploit local cues to regulate release kinetics after cellular entry [29]. This makes release time inseparable from trafficking state. A rapid response in the wrong compartment can be as ineffective as a slow response at the intended target.

Sequential-release systems provide a stronger test of this principle. In triple-negative breast cancer models, a redox-activatable nanoparticle was designed for site-specific sequential release of therapeutic components affecting cellular metabolism, gene regulation, and the tumor immune microenvironment [30]. The result demonstrates that payload order can be engineered and linked to distinct biological processes. It does not establish one universal sequence. The appropriate order depends on cargo mechanism, intracellular trafficking, target turnover, cell type, disease state, and the time required for an upstream intervention to reshape a downstream condition.

Timing therefore creates a second precision problem after access. A carrier can arrive at the correct tissue yet release before cell internalization, remain intact after reaching the cytosol, or activate only after the target state has disappeared. Conversely, delayed release may be advantageous when carrier trafficking is required before the active agent should become available. The relevant question is not whether release is "fast," "slow," or "sustained," but whether it is synchronized with the state transition that makes the payload useful.

Table 2 separates the intracellular states that are often compressed into a single uptake-to-release arrow. The distinctions matter because the dominant sink, local biological identity, trigger availability, and relevant measurement scale change as a particle traverses the cell.

Table 2. Temporal states that determine whether payload release is synchronized with intracellular delivery

State and entry conditions		Evidence through time	Transition and reassessment
Trafficking state / Dominant barrier or sink	**transport event / Local biological identity**	**Entry condition / Most informative measurement scale**	**matching endpoint**
Trafficking state: Cell-surface association Dominant barrier or sink: Nonspecific adsorption, membrane shedding, extracellular retention	**Required transport event:** Productive receptor interaction or membrane engagement **Local biological identity:** Protein-corona-modified carrier at cell interface	**Entry condition:** Carrier reaches a target-accessible membrane region **Most informative measurement scale:** Single-cell and membrane-resolved	Association persists long enough to support productive internalization without premature release
Trafficking state: Internalization Dominant barrier or sink: Nonproductive uptake route or recycling	**Required transport event:** Endocytic or alternative internalization **Local biological identity:** Membrane-enclosed internalized carrier	**Entry condition:** Surface-bound carrier enters the cell **Most informative measurement scale:** Live-cell trafficking	Uptake route remains compatible with the intended downstream release mechanism
Trafficking state: Early endosomal residence Dominant barrier or sink: Recycling to membrane or sequestration	**Required transport event:** Progression toward escape or selected endosomal processing **Local biological identity:** Acidifying vesicle-associated state	**Entry condition:** Carrier experiences initial endosomal processing **Most informative measurement scale:** Subcellular time-resolved	Trigger activation begins only if early endosomal release is pharmacologically intended
Trafficking state: Late endosomal or lysosomal progression Dominant barrier or sink: Lysosomal sequestration and cargo degradation	**Required transport event:** Escape, controlled degradation, or deliberate lysosomal delivery **Local biological identity:** Low-pH, enzyme-rich vesicular state	**Entry condition:** Carrier enters increasingly degradative compartments **Most informative measurement scale:** Organelle-resolved	Carrier transformation is matched to whether lysosomal processing is desired or must be avoided
Trafficking state: Endosomal escape Dominant barrier or sink: Incomplete escape or membrane-associated loss	**Required transport event:** Cytosolic translocation **Local biological identity:** Partially transformed carrier and newly available payload	**Entry condition:** Carrier crosses the vesicular membrane **Most informative measurement scale:** Cytosolic delivery assay	Release and escape occur in an order that preserves active payload
Trafficking state: Cytosolic transit Dominant barrier or sink: Degradation, binding to off-target sinks, rapid diffusion	**Required transport event:** Movement toward molecular or organelle target **Local biological identity:** Free or partially carrier-associated payload	**Entry condition:** Payload becomes exposed to cytosolic enzymes and redox chemistry **Most informative measurement scale:** Molecular and subcellular	Pharmacologically active species appears while the relevant target state persists
Trafficking state: Target or organelle engagement Dominant barrier or sink: Late arrival after biological adaptation or target loss	**Required transport event:** Target binding, gene editing, metabolic action, or organelle accumulation **Local biological identity:** Therapeutically active state	**Entry condition:** Payload reaches the intended intracellular site **Most informative measurement scale:** Target-engagement or functional assay	Release timing is judged by target engagement rather than by carrier disassembly alone

A second figure is needed because affinity, tumor accumulation, internalization, and release are frequently represented as one favorable trajectory, whereas the manuscript requires explicit gates between access and timed pharmacological availability.




Figure 2. High affinity cannot compensate for missed access or mistimed payload availability

When stimulus responsiveness becomes mismatched

Stimulus responsiveness is usually demonstrated by showing that a carrier changes structure, degrades, exposes a ligand, or releases cargo under a selected condition. That experiment establishes chemical or physical responsivity; it does not establish biological matching. Mismatch occurs when the trigger–carrier interaction is valid in principle but unavailable or incorrectly timed during actual transport. The failure may originate upstream from the responsive chemistry itself. A hypoxia-sensitive carrier, for example, can remain inactive because inadequate perfusion prevents sufficient carrier from reaching the hypoxic region. Conversely, a pH-sensitive system can transform before reaching the intended intracellular compartment if its transition range overlaps with conditions encountered earlier in delivery [16].

At least five mismatch classes emerge from the evidence considered here. Access mismatch occurs when a carrier cannot reach the region containing its intended trigger. Intensity mismatch occurs when the local biochemical state is insufficient, excessive, or too heterogeneous for reproducible transformation. Compartment mismatch occurs when responsiveness is activated in a biological location different from that required for payload action. Temporal mismatch occurs when the trigger appears before or after the useful therapeutic window. Feedback mismatch occurs when treatment changes the microenvironment so that subsequent carrier populations face conditions different from those used to select the original formulation. These categories constitute a proposed diagnostic taxonomy, not an empirically validated classification.

Importantly, a negative response does not by itself reveal which mismatch has occurred. The vascular-access evidence described earlier shows that tumor entry can be spatially restricted [8]. Imaging can characterize some components of permeability and retention but does not measure all later delivery stages [10]. Similarly, tumor-dependent responses to ultrasound-mediated delivery demonstrate that failure to improve penetration may reflect tissue composition rather than inadequate carrier responsiveness [11]. A mechanistic assessment should therefore distinguish failure to reach the trigger from failure to respond after reaching it.

External stimuli create an additional mismatch category because stimulus delivery itself becomes a controlled exposure. Nanoparticle-mediated photothermal and magnetothermal approaches illustrate that therapeutic outcome depends on particle properties, tissue distribution, energy delivery, heat measurement, and physiologically relevant validation models [31]. These constraints should not be generalized directly to every responsive nanomedicine, but they demonstrate a broader principle: a trigger must be characterized not only by its existence but by its spatial distribution, dose or intensity, timing, and relationship to carrier localization.

Table 3 organizes these failure patterns as competing diagnoses rather than as a ranking of responsive technologies.

Table 3. Distinguishing true stimulus failure from upstream and downstream carrier–microenvironment mismatch

Observed configuration	Mechanism and competing diagnosis	Corrective discrimination
Observable signature	**Observed failure pattern / Likely origin / Competing diagnosis**	**Corrective test / Residual consequence after correction**
Trigger detected in tissue but little colocalization with carrier	**Observed failure pattern:** Minimal carrier activation despite a disease-associated trigger **Likely origin:** Inadequate carrier access to trigger-rich region **Competing diagnosis:** Responsive chemistry lacks sufficient sensitivity	**Corrective test:** Spatially co-measure carrier abundance, trigger state, and transformation product **Residual consequence after correction:** Improved sensitivity remains irrelevant if access stays poor
Carrier transformation precedes intended cellular or organelle entry	**Observed failure pattern:** Activation occurs earlier than intended **Likely origin:** Trigger overlap in an upstream compartment **Competing diagnosis:** Premature degradation caused by nonspecific biological interactions	**Corrective test:** Follow intact carrier and released payload across sequential compartments **Residual consequence after correction:** Earlier release may increase off-target exposure even after trigger specificity is improved
Tissue accumulation with low intracellular free-payload signal	**Observed failure pattern:** Carrier reaches target tissue but payload remains unavailable **Likely origin:** Trafficking or release mismatch **Competing diagnosis:** Payload potency or target engagement is intrinsically weak	**Corrective test:** Pair trafficking measurements with direct payload-availability and target-engagement assays **Residual consequence after correction:** Successful accumulation still cannot establish pharmacological delivery
Responsive-state signal varies among tumor regions	**Observed failure pattern:** Large interregional variation in activation **Likely origin:** Spatially heterogeneous trigger intensity or access **Competing diagnosis:** Uneven nanoparticle deposition alone	**Corrective test:** Map trigger state and carrier concentration independently at matched spatial resolution **Residual consequence after correction:** Regional matching may be required rather than a tumor-wide design assumption
Longitudinal trigger measurements diverge from pretreatment values	**Observed failure pattern:** Response observed during initial treatment but declines later **Likely origin:** Treatment-induced microenvironment remodeling **Competing diagnosis:** Carrier degradation or altered systemic pharmacokinetics	**Corrective test:** Repeat state, PK, access, and activation measurements across treatment cycles **Residual consequence after correction:** A previously appropriate formulation may become biologically mismatched
Carrier transformation confirmed without proportional target engagement	**Observed failure pattern:** Strong activation without corresponding therapeutic action **Likely origin:** Trigger fidelity is correct but release timing, compartment, or payload biology is wrong **Competing diagnosis:** Disease resistance independent of delivery	**Corrective test:** Measure active payload, target engagement, and downstream response after confirmed activation **Residual consequence after correction:** Responsiveness should not be interpreted as delivery success

The practical implication is that failure analysis should begin with the earliest point at which carrier behavior diverges from the required biological state. Increasing stimulus sensitivity is rational only when insufficient transformation is genuinely the limiting step. If the dominant problem is vascular access, interstitial transport, cellular trafficking, or payload pharmacology, making the responsive linkage more sensitive can increase premature activation without solving the actual bottleneck.

A carrier–microenvironment matching framework

We therefore propose a carrier–microenvironment matching framework built around state correspondence rather than carrier sophistication. Its first requirement is to define the biological state relevant to a specific delivery function. Vascular permeability or endothelial transport should be linked to tissue access; extracellular-matrix organization to interstitial propagation; biochemical cues to carrier transformation; intracellular trafficking to

compartmental release; and target state to pharmacological action. These variables should not be merged into a single concept of "tumor targeting."

The second requirement is an explicit access gate. Evidence that nanoparticle entry can depend on active endothelial transport means that the presence of an attractive downstream trigger cannot substitute for evidence that the carrier reaches that trigger [8]. Likewise, enzyme-responsive chemistry should be interpreted only after active enzyme and carrier are shown to occupy the same relevant compartment [23]. The proposed framework therefore separates *accessibility of the state* from *responsiveness to the state*.

The third requirement is a state-transition gate. A responsive carrier should be evaluated as a succession of material states rather than as one fixed nanoparticle. Surface interactions can alter biological identity during circulation [12]; environmental cues can change structural organization [6]; intracellular conditions can alter degradation or release [29]. The question at each transition is whether the new carrier state improves the next required function without compromising an earlier or later one.

The fourth requirement is a temporal payload gate. Spatial localization and release kinetics are linked but not equivalent [5]. Payload should become pharmacologically available when its target is accessible and biologically relevant, not merely when carrier degradation is detectable. Sequential-release systems demonstrate that ordering can be deliberately engineered [30], while treatment-induced immune or stromal remodeling shows that the target environment itself may change after the first intervention [27].

Finally, the framework includes a feedback channel. Therapy can alter macrophage state, fibrosis, oxygenation, metabolism, redox balance, vascular function, or other microenvironmental features [24]. Such changes may improve subsequent access, abolish a required trigger, generate a new barrier, or alter which carrier function is limiting. For repeated dosing, matching should therefore be considered potentially iterative rather than a one-time pretreatment assignment.

This architecture is intentionally conceptual. It does not generate a patient-selection score, predict clinical response, rank nanocarriers, or prescribe numerical thresholds. Its purpose is narrower: to prevent mechanistically distinct requirements—access, activation, release, and action—from being interpreted as though evidence for one establishes the others.

Experimental validation across disease stages

Validation of this framework requires experiments that challenge the carrier across changing disease states rather than under one optimized condition. A useful design should begin by measuring the microenvironmental variable that the carrier is intended to exploit and the carrier's actual exposure to that variable. Imaging approaches capable of characterizing permeability or retention provide one possible component of such assessment [10], but access measurements should be paired with measurements of carrier transformation, released payload, and target engagement.

Longitudinal designs are particularly important because microenvironmental states may change during progression or therapy. Spatial TME heterogeneity argues against assuming that a single pretreatment biopsy or bulk tumor measurement represents every delivery region [3]. Similarly, evidence that treatment can remodel immune and stromal conditions means that later doses may encounter a different transport and activation landscape [27]. Stage-aware validation should therefore compare relevant disease stages or treatment states while keeping carrier composition, dose, administration route, and measurement procedures controlled.

Trigger fidelity should also be separated experimentally from therapeutic efficacy. For a pH-, hypoxia-, redox-, or enzyme-responsive carrier, the first question is whether the intended state causes the predicted material transformation under physiologically credible conditions. The next is whether that transformation occurs after the carrier reaches the intended compartment. Only afterward should payload availability, target engagement, and downstream therapeutic response be interpreted. This ordering helps prevent an efficacy signal caused by unrelated carrier or payload effects from being misclassified as validation of the responsive mechanism.

Orthogonal measurements are preferable where feasible. A responsive-system study can combine spatial carrier localization with an independent measurement of the relevant biochemical state, a direct readout of carrier transformation, quantification of pharmacologically available payload, and a target-engagement assay. Null or discordant results are informative: abundant trigger with little carrier transformation implicates access or response chemistry, whereas robust transformation without target engagement points toward release, trafficking, or pharmacological mismatch.

Preclinical-to-clinical transfer requires an additional boundary. Translational analyses of oncology nanomedicine emphasize that pharmacokinetics, immunological interactions, toxicity, and other host-level factors remain

important even when formulation-level mechanisms are compelling [2]. Thermal nanomedicine similarly illustrates the need for realistic screening models, reproducible stimulus delivery, dosimetry, and measurement of the actual physical exposure produced in tissue [31]. The proposed matching framework therefore should not be considered validated by success in a single responsive-cell assay or one tumor model.

A stronger validation program would test whether a carrier retains the intended relationship between biological state and function across model systems, disease stages, treatment cycles, and relevant interindividual variability. Failure should not automatically eliminate the platform. Instead, the location of failure should identify whether redesign is needed at the level of access, biological identity, stimulus calibration, trafficking, release kinetics, or payload pharmacology. Such experiments would convert "responsiveness" from a material descriptor into a falsifiable delivery hypothesis.

CONCLUSION

Precision nanomedicine depends on more than engineering carriers that recognize targets or respond to disease-associated stimuli. The biological states governing nanoparticle entry, interstitial transport, cellular uptake, biochemical activation, intracellular trafficking, and payload action vary across space and can change during treatment. A carrier can therefore be chemically responsive yet biologically mismatched.

The proposed carrier–microenvironment matching framework separates access, carrier-state transition, timed payload availability, and pharmacological action while incorporating feedback from treatment-induced remodeling. Its principal purpose is diagnostic: it identifies where evidence for one delivery stage should not be used to infer success at another. It does not establish universal thresholds, predict patient benefit, or demonstrate that adaptive nanocarriers are intrinsically superior to simpler formulations.

Progress toward precision delivery will require longitudinal and spatially resolved validation in which the relevant disease state, carrier exposure, carrier transformation, payload availability, and target engagement are measured as distinct quantities. Under that standard, responsiveness becomes useful not when a nanoparticle reacts to a stimulus in isolation, but when the reaction occurs in the correct biological compartment, at the correct stage of delivery, and while the resulting payload remains pharmacologically relevant.

ACKNOWLEDGMENTS: None

CONFLICT OF INTEREST: None

FINANCIAL SUPPORT: None

ETHICS STATEMENT: None

REFERENCES

1. Liu J, Cabral H, Mi P. Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release. Adv Drug Deliv Rev. 2024;207:115239. doi:10.1016/j.addr.2024.115239
2. Gabizon AA, de Rosales RTM, La-Beck NM. Translational considerations in nanomedicine: The oncology perspective. Adv Drug Deliv Rev. 2020;158:140-57. doi:10.1016/j.addr.2020.05.012
3. Hwang JE, Park J, Kim HS, Li S, Im HJ. Tumor microenvironment-specific nanomedicine: From biology-driven to multi-omics-guided precision engineering. J Hematol Oncol. 2026;19(1):56. doi:10.1186/s13045-026-01811-9
4. Han H, Xing L, Chen BT, Liu Y, Zhou TJ, Wang Y, et al. Progress on the pathological tissue microenvironment barrier-modulated nanomedicine. Adv Drug Deliv Rev. 2023;200:115051. doi:10.1016/j.addr.2023.115051
5. Qin M, Xia H, Xu W, Chen B, Wang Y. The spatiotemporal journey of nanomedicines in solid tumors on their therapeutic efficacy. Adv Drug Deliv Rev. 2023;203:115137. doi:10.1016/j.addr.2023.115137
6. Yang Y, Wu H, Liu B, Liu Z. Tumor microenvironment-responsive dynamic inorganic nanoassemblies for cancer imaging and treatment. Adv Drug Deliv Rev. 2021;179:114004. doi:10.1016/j.addr.2021.114004

7. Ding X, Liang Y, Zhou S, Wu Y, Sałata P, Mikolajczk-Martinez A, et al. Targeting tumor extracellular matrix with nanoparticles to circumvent therapeutic resistance. J Control Release. 2025;383:113786. doi:10.1016/j.jconrel.2025.113786
8. Sindhwani S, Syed AM, Ngai J, Kingston BR, Maiorino L, Rothschild J, et al. The entry of nanoparticles into solid tumours. Nat Mater. 2020;19(5):566-75. doi:10.1038/s41563-019-0566-2
9. Kingston BR, Lin ZP, Ouyang B, MacMillan P, Ngai J, Syed AM, et al. Specific endothelial cells govern nanoparticle entry into solid tumors. ACS Nano. 2021;15(9):14080-94. doi:10.1021/acsnano.1c04510
10. Nomani A, Yousefi S, Sargsyan D, Hatefi A. A quantitative MRI-based approach to estimate the permeation and retention of nanomedicines in tumors. J Control Release. 2024;368:728-39. doi:10.1016/j.jconrel.2024.03.019
11. Einen C, Snipstad S, Wesche HF, Nordlund V, Devold EJ, Amini N, et al. Impact of the tumor microenvironment on delivery of nanomedicine in tumors treated with ultrasound and microbubbles. J Control Release. 2025;378:656-70. doi:10.1016/j.jconrel.2024.12.037
12. Grundler J, Shin K, Suh HW, Whang CH, Fulgoni G, Pierce RW, et al. Nanoscale surface topography of polyethylene glycol-coated nanoparticles composed of bottlebrush block copolymers prolongs systemic circulation and enhances tumor uptake. ACS Nano. 2024;18(4):2815-27. doi:10.1021/acsnano.3c05921
13. Liu Y, Zhou J, Li Q, Li L, Jia Y, Geng F, et al. Tumor microenvironment remodeling-based penetration strategies to amplify nanodrug accessibility to tumor parenchyma. Adv Drug Deliv Rev. 2021;172:80-103. doi:10.1016/j.addr.2021.02.019
14. Jiang X, Fan X, Xu W, Zhao C, Wu H, Zhang R, et al. Self-assembled peptide nanoparticles responsive to multiple tumor microenvironment triggers provide highly efficient targeted delivery and release of antitumor drug. J Control Release. 2019;316:196-207. doi:10.1016/j.jconrel.2019.10.031
15. Xiao H, Li X, Liang S, Yang S, Han S, Huang J, et al. Dual-responsive nanomedicine activates programmed antitumor immunity through targeting lymphatic system. ACS Nano. 2024;18(17):11070-83. doi:10.1021/acsnano.3c11464
16. Ma X, Yang Q, Lin N, Feng Y, Liu Y, Liu P, et al. Integrated anti-vascular and immune-chemotherapy for colorectal carcinoma using a pH-responsive polymeric delivery system. J Control Release. 2024;370:230-8. doi:10.1016/j.jconrel.2024.04.028
17. Zhang B, Qin C, Wang X, Shen C, Li S, Liu T, et al. Hybrid prodrug nanoassembly for hypoxia-triggered immunogenic chemotherapy and immune modulation. J Control Release. 2025;379:221-35. doi:10.1016/j.jconrel.2025.01.008
18. Qu C, Kang XZ, Li J, Kan XY, Luan Y, Ning D. Biomimetic lipid nanocarriers overcome hypoxia barriers in lung cancer therapy. J Control Release. 2025;386:114099. doi:10.1016/j.jconrel.2025.114099
19. Liu D, Liang M, Tao Y, Liu H, Liu Q, Bing W, et al. Hypoxia-accelerating pyroptosis nanoinducers for promoting image-guided cancer immunotherapy. Biomaterials. 2024;309:122610. doi:10.1016/j.biomaterials.2024.122610
20. Fan Z, Wu S, Deng H, Li G, Huang L, Liu H. Light-triggered nanozymes remodel the tumor hypoxic and immunosuppressive microenvironment for ferroptosis-enhanced antitumor immunity. ACS Nano. 2024;18(19):12261-75. doi:10.1021/acsnano.4c00844
21. He J, Zhang X, Xing H, Tan J, Zhang L, Xu Z, et al. Nanoparticle-mediated synergistic disruption of tumor innervation and redox homeostasis for potent antineoplastic therapy. J Control Release. 2024;376:457-69. doi:10.1016/j.jconrel.2024.10.039
22. Sang R, Yang B, Zahra K, Deng F, Gu Z, Goldys EM, et al. Redox responsive nanosystems for medicine: From reactive species mapping to precision treatment. Adv Drug Deliv Rev. 2026;235:115892. doi:10.1016/j.addr.2026.115892
23. Shahriari M, Zahiri M, Abnous K, Taghdisi SM, Ramezani M, Alibolandi M. Enzyme responsive drug delivery systems in cancer treatment. J Control Release. 2019;308:172-89. doi:10.1016/j.jconrel.2019.07.004
24. Hu Y, Nie W, Lyu L, Zhang X, Wang W, Zhang Y, et al. Tumor-microenvironment-activatable nanoparticle mediating immunogene therapy and M2 macrophage-targeted inhibitor for synergistic cancer immunotherapy. ACS Nano. 2024;18(4):3295-312. doi:10.1021/acsnano.3c10037
25. Zhou Y, Yuan J, Xu K, Li S, Liu Y. Nanotechnology reprogramming metabolism for enhanced tumor immunotherapy. ACS Nano. 2024;18(3):1846-64. doi:10.1021/acsnano.3c11260

26. Yin X, Zhao X, Shen Y, Xie W, He C, Guo J, et al. Nanoparticle-mediated dual targeting of stromal and immune components to overcome fibrotic and immunosuppressive barriers in hepatocellular carcinoma. J Control Release. 2025;383:113783. doi:10.1016/j.jconrel.2025.113783
27. Zhao H, Du F, Huang J, Guo R, Feng Z, Wang Z, et al. Biomimetic liposomal nanovesicles remodel the tumor immune microenvironment to augment sono-immunotherapy. J Control Release. 2025;383:113830. doi:10.1016/j.jconrel.2025.113830
28. Udofa E, Zhao Z. In situ cellular hitchhiking of nanoparticles for drug delivery. Adv Drug Deliv Rev. 2024;204:115143. doi:10.1016/j.addr.2023.115143
29. Sun T, Jiang C. Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments. Adv Drug Deliv Rev. 2023;196:114773. doi:10.1016/j.addr.2023.114773
30. She W, Li H, Wang Z, Liu T, Zhao D, Guo Z, et al. Site-specific controlled-release nanoparticles for immune reprogramming via dual metabolic inhibition against triple-negative breast cancer. J Control Release. 2024;366:204-20. doi:10.1016/j.jconrel.2023.12.022
31. Bravo M, Fortuni B, Mulvaney P, Hofkens J, Uji-I H, Rocha S, et al. Nanoparticle-mediated thermal cancer therapies: Strategies to improve clinical translatability. J Control Release. 2024;372:751-77. doi:10.1016/j.jconrel.2024.06.055